1-甲基-3-亚甲基-哌啶-4-酮 | 133828-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲基-3-亚甲基-哌啶-4-酮
• 中文别名: 4-哌啶酮,1-甲基-3-亚甲基-(9CI)
• 英文名称: 1-Methyl-3-methylidenepiperidin-4-one
• CAS: 133828-19-0
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: MVFXJLXCEXZNBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NOVEL COMPOUNDS AS BTK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE BTK
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2017168454A2

  公开（公告）日：2017-10-05

  The present invention relates to novel compounds of Formula I as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation 5 of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.
• [EN] NOVEL HYDRAZINO COMPOUNDS AS BTK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HYDRAZINO UTILISÉS COMME INHIBITEURS DE BTK
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2017134685A2

  公开（公告）日：2017-08-10

  The present invention relates to novel hydrazino compounds of Formula (I) as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.